What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis

Review (15 RCTs; n=8995) suggests that avelumab plus axitinib might be the optimum treatment for advanced/metastatic renal cell carcinoma of favourable risk and pembrolizumab plus axitinib might be the optimum treatment for intermediate-risk and poor-risk patients.

BMJ Open